Co-expression of Cancer Stem Cell Markers, SALL4/ALDH1A1, is Associated with Tumor Aggressiveness and Poor Survival in Patients with Serous Ovarian Carcinoma

Overview

Journal J Ovarian Res

Publisher Biomed Central

Specialties Gynecology & Obstetrics
Reproductive Medicine

Date 2022 Jan 29

PMID 35090523

Authors

Mina Sharbatoghli

Parisa Shamshiripour

Fahimeh Fattahi

Elham Kalantari

Zohre Habibi Shams

Mahshid Panahi

Mehdi Totonchi

Zeynab Asadi-Lari

Zahra Madjd

Leili Saeednejad Zanjani

Affiliations

Soon will be listed here.

Abstract

Background: Spalt-like transcription factor 4 (SALL4) and aldehyde dehydrogenase1 family member A1 (ALDH1A1) expressing cells have been characterized as possessing stem cell-like properties known as cancer stem cell marker in serous ovarian carcinoma (SOC).

Methods: The association between SALL4 and ALDH1A1 was observed based on literature review and bioinformatics tools. Therefore, this study aimed to investigate the association between the co-expression of SALL4/ALDH1A1 proteins and clinicopathological parameters and their prognostic value in SOC patients using immunohistochemical staining on tissue microarrays (TMAs). Furthermore, benign tumors and normal tissue samples were compared with the expression of the tumor tissue samples.

Results: Increased co-expression of SALL4/ALDH1A1 was found to be significantly associated with the advanced FIGO stage (P = 0.047), and distant metastasis (P = 0.028). The results of Kaplan-Meier survival analysis indicated significant differences between disease- specific survival (DSS; P = 0.034) or progression-free survival (PFS; P = 0.018) and the patients with high and low co-expression of SALL4/ALDH1A1, respectively. Furthermore, high level co-expression of SALL4/ALDH1A1 was a significant predictor of worse DSS and PFS in the univariate analysis. The data also indicated that the co-expression of SALL4/ALDH1A1 was an independent prognostic factor affecting PFS. Moreover, the co-expression of SALL4/ALDH1A1 added prognostic values of DSS in patients with SOC who had grade III versus grade I in multivariate analysis.

Conclusions: Our data demonstrated that high co-expression of SALL4/ALDH1A1 was found to be significantly associated with tumor aggressiveness and worse DSS or PFS in SOC patients. Therefore, co-expression of SALL4/ALDH1A1 may serve as a potential prognostic biomarker of cancer progression in these cases.

Citing Articles

Cytoplasmic SALL4-A isoform expression as a diagnostic marker of less aggressive tumor behavior in gastric cancer.

Rahmani S, Babajani A, Abolhasani M, Ghods R, Kalantari E, Madjd Z World J Surg Oncol. 2025; 23(1):41.

PMID: 39905414 PMC: 11796022. DOI: 10.1186/s12957-025-03681-w.

Aldehyde Dehydrogenase-1A1 (ALDH1A1): The Novel Regulator of Chemoresistance in Pancreatic Cancer Cells.

Duong H, Hoang M, Nguyen T, Nguyen P, Le V, Dao T Cancer Control. 2024; 31:10732748241305835.

PMID: 39611960 PMC: 11607765. DOI: 10.1177/10732748241305835.

Cancer stem cells: advances in knowledge and implications for cancer therapy.

Chu X, Tian W, Ning J, Xiao G, Zhou Y, Wang Z Signal Transduct Target Ther. 2024; 9(1):170.

PMID: 38965243 PMC: 11224386. DOI: 10.1038/s41392-024-01851-y.

SALL4 in gastrointestinal tract cancers: upstream and downstream regulatory mechanisms.

Wang T, Jin Y, Wang M, Chen B, Sun J, Zhang J Mol Med. 2024; 30(1):46.

PMID: 38584262 PMC: 11000312. DOI: 10.1186/s10020-024-00812-z.

Defining the Role of Metastasis-Initiating Cells in Promoting Carcinogenesis in Ovarian Cancer.

Wang J, Ford J, Mitra A Biology (Basel). 2023; 12(12).

PMID: 38132318 PMC: 10740540. DOI: 10.3390/biology12121492.

References

Franz M, Rodriguez H, Lopes C, Zuberi K, Montojo J, Bader G . GeneMANIA update 2018. Nucleic Acids Res. 2018; 46(W1):W60-W64. PMC: 6030815. DOI: 10.1093/nar/gky311. View

Chen T, Tsang J, Su X, Li P, Sun W, Wong I . SALL4 promotes tumor progression in breast cancer by targeting EMT. Mol Carcinog. 2020; 59(10):1209-1226. DOI: 10.1002/mc.23250. View

Xiang Y, Yang T, Pang B, Zhu Y, Liu Y . The Progress and Prospects of Putative Biomarkers for Liver Cancer Stem Cells in Hepatocellular Carcinoma. Stem Cells Int. 2016; 2016:7614971. PMC: 5005617. DOI: 10.1155/2016/7614971. View

Shannon P, Markiel A, Ozier O, Baliga N, Wang J, Ramage D . Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003; 13(11):2498-504. PMC: 403769. DOI: 10.1101/gr.1239303. View

Ratajczak M, Ratajczak J, Suszynska M, Miller D, Kucia M, Shin D . A Novel View of the Adult Stem Cell Compartment From the Perspective of a Quiescent Population of Very Small Embryonic-Like Stem Cells. Circ Res. 2017; 120(1):166-178. PMC: 5221475. DOI: 10.1161/CIRCRESAHA.116.309362. View

Liu L, Zhang J, Yang X, Fang C, Xu H, Xi X . SALL4 as an Epithelial-Mesenchymal Transition and Drug Resistance Inducer through the Regulation of c-Myc in Endometrial Cancer. PLoS One. 2015; 10(9):e0138515. PMC: 4583418. DOI: 10.1371/journal.pone.0138515. View

Mei K, Liu A, Allan R, Wang P, Lane Z, Abel T . Diagnostic utility of SALL4 in primary germ cell tumors of the central nervous system: a study of 77 cases. Mod Pathol. 2009; 22(12):1628-36. DOI: 10.1038/modpathol.2009.148. View

Zhang L, Xu Z, Xu X, Zhang B, Wu H, Wang M . SALL4, a novel marker for human gastric carcinogenesis and metastasis. Oncogene. 2013; 33(48):5491-500. DOI: 10.1038/onc.2013.495. View

Desai A, Xu J, Aysola K, Qin Y, Okoli C, Hariprasad R . Epithelial ovarian cancer: An overview. World J Transl Med. 2014; 3(1):1-8. PMC: 4267287. DOI: 10.5528/wjtm.v3.i1.1. View

10.

Lin N, Hsu J, Tsai K . Survival and clinicopathological characteristics of different histological grades of oral cavity squamous cell carcinoma: A single-center retrospective study. PLoS One. 2020; 15(8):e0238103. PMC: 7447052. DOI: 10.1371/journal.pone.0238103. View

11.

Kryczek I, Liu S, Roh M, Vatan L, Szeliga W, Wei S . Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int J Cancer. 2011; 130(1):29-39. PMC: 3164893. DOI: 10.1002/ijc.25967. View

12.

Zhang X, Yuan X, Zhu W, Qian H, Xu W . SALL4: an emerging cancer biomarker and target. Cancer Lett. 2014; 357(1):55-62. DOI: 10.1016/j.canlet.2014.11.037. View

13.

Walcher L, Kistenmacher A, Suo H, Kitte R, Dluczek S, Strauss A . Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies. Front Immunol. 2020; 11:1280. PMC: 7426526. DOI: 10.3389/fimmu.2020.01280. View

14.

Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A . ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009; 25(8):1091-3. PMC: 2666812. DOI: 10.1093/bioinformatics/btp101. View

15.

Cao D, Guo S, Allan R, Molberg K, Peng Y . SALL4 is a novel sensitive and specific marker of ovarian primitive germ cell tumors and is particularly useful in distinguishing yolk sac tumor from clear cell carcinoma. Am J Surg Pathol. 2009; 33(6):894-904. DOI: 10.1097/PAS.0b013e318198177d. View

16.

Chui M, Wang Y, Wu R, Seidman J, Kurman R, Wang T . Loss of ALDH1A1 expression is an early event in the pathogenesis of ovarian high-grade serous carcinoma. Mod Pathol. 2014; 28(3):437-45. PMC: 4344882. DOI: 10.1038/modpathol.2014.89. View

17.

Nwani N, Condello S, Wang Y, Swetzig W, Barber E, Hurley T . A Novel ALDH1A1 Inhibitor Targets Cells with Stem Cell Characteristics in Ovarian Cancer. Cancers (Basel). 2019; 11(4). PMC: 6521036. DOI: 10.3390/cancers11040502. View

18.

Zhou C, Sun B . The prognostic role of the cancer stem cell marker aldehyde dehydrogenase 1 in head and neck squamous cell carcinomas: a meta-analysis. Oral Oncol. 2014; 50(12):1144-8. DOI: 10.1016/j.oraloncology.2014.08.018. View

19.

Kobayashi D, Kuribayashi K, Tanaka M, Watanabe N . Overexpression of SALL4 in lung cancer and its importance in cell proliferation. Oncol Rep. 2011; 26(4):965-70. DOI: 10.3892/or.2011.1374. View

20.

Sidiropoulos K, Viteri G, Sevilla C, Jupe S, Webber M, Orlic-Milacic M . Reactome enhanced pathway visualization. Bioinformatics. 2017; 33(21):3461-3467. PMC: 5860170. DOI: 10.1093/bioinformatics/btx441. View